1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
32.15%
Cash & equivalents changing by 32.15% while Biotechnology maintains stable levels. Benjamin Graham would examine if this divergence is justified.
No Data
No Data available this quarter, please select a different quarter.
32.15%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.78%
Current assets growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-2.88%
PP&E growth below half of Biotechnology median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.86%
Below half the Biotechnology median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
30.51%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
63.16%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.70%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
49.30%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.30%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
16.87%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-5.16%
≥ 1.5x Biotechnology median of -1.82%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-13.18%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
26.52%
Below half Biotechnology median of -0.02%. Jim Chanos suspects slower net worth growth or losses vs. peers.
30.51%
≥ 1.5x Biotechnology median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-32.15%
Above 1.5x Biotechnology median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
